AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7419561 — intervention group
Group type: COMPARATOR
Intervention: Control group without antithrombotic therapy
Number of subjects: 389
Study 31779683 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness-Based Childbirth and Parenting (MBCP) program + treatment as usual (TAU)
Number of subjects: 122
Study 31779683 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 122
Study 28953037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Blood Spots (DBS)
Number of subjects: 630
Study 28953037 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS-predicted plasma values
Number of subjects: 630
Study 28953037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive DBS sampling
Number of subjects: 630
Study 26523692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-valued pairs
Number of subjects: 0
Study 26523692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-valued pairs
Number of subjects: 0
Study 26523692 — intervention group
Group type: EXPERIMENTAL
Intervention: Normatively effective encoding strategies
Number of subjects: 0
Study 26523692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intelligence
Number of subjects: 0
Study 24253250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/daily)
Number of subjects: 0
Study 24253250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20881400 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous treatment for quitting both alcohol and tobacco
Number of subjects: 92
Study 20881400 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (help to quit smoking after 6 months)
Number of subjects: 92
Study 19016404 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR‐5 extract (576 mg extract/day)
Number of subjects: 60
Study 19016404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four tablets daily)
Number of subjects: 60
Study 17589283 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-to-Heart (HTH) walking program
Number of subjects: 46
Study 17589283 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 46
Study 15460213 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized European mistletoe extract (Viscum album L., Iscador) given in addition to conventional adjuvant oncologic therapy for at least three months.
Number of subjects: 1442
Study 15460213 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (control group).
Number of subjects: 1442
Study 15460213 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized European mistletoe extract (Viscum album L., Iscador) given in addition to conventional adjuvant oncologic therapy.
Number of subjects: 1442
Study 11585017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (OCs)
Number of subjects: 0
Study 11585017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9613295 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1, 2, 3, 4, 5 or 6 micrograms.ml‐1) and Sufentanil (0.1, 0.2, 0.3, 0.5 or 1.0 ng.ml‐1) target concentrations for induction of anaesthesia
Number of subjects: 30
Study 9613295 — intervention group
Group type: EXPERIMENTAL
Intervention: Median frequency
Number of subjects: 30
Study 7924126 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol with normoxia-normocapnia gas mixture
Number of subjects: 9
Study 7924126 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol with hypercapnia gas mixture
Number of subjects: 9
Study 7924126 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol with hypoxemia-hypercapnia gas mixture
Number of subjects: 9
Study 7924126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (end-tidal PaCO2, 50 mm Hg)
Number of subjects: 9
Study 7924126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxemia-hypercapnia (arterial oxygen saturation, 90%; PaCO2, 50 mm Hg)
Number of subjects: 9
Study 31651206 — intervention group
Group type: EXPERIMENTAL
Intervention: C2Hear reusable learning objects (RLOs)
Number of subjects: 56
Study 31651206 — intervention group
Group type: COMPARATOR
Intervention: Printed booklet on hearing aids (Control)
Number of subjects: 56
Study 31004126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation (tPBM) using NIR light (810 nm, pulsed at 40 Hz)
Number of subjects: 0
Study 31004126 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 27858673 — intervention group
Group type: COMPARATOR
Intervention: Single suprascapular nerve block (SSNB)
Number of subjects: 96
Study 27858673 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple (nine) suprascapular nerve blocks (SSNB)
Number of subjects: 96
Study 26939326 — intervention group
Group type: EXPERIMENTAL
Intervention: Encircling needling combined with physical factor therapy
Number of subjects: 34
Study 26939326 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing, ultrasonic wave and short-wave ultraviolet therapy (Control group)
Number of subjects: 34
Study 23973694 — intervention group
Group type: COMPARATOR
Intervention: Circumferential PVI
Number of subjects: 242
Study 23973694 — intervention group
Group type: COMPARATOR
Intervention: Anatomic ablation of the main left atrial GP
Number of subjects: 242
Study 23973694 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential PVI followed by anatomic ablation of the main left atrial GP
Number of subjects: 242
Study 20570416 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube test (QFG-IT)
Number of subjects: 118
Study 20570416 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin test
Number of subjects: 118
Study 17763228 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact catheter
Number of subjects: 24
Study 17763228 — intervention group
Group type: COMPARATOR
Intervention: Standard-length female catheter
Number of subjects: 24
Study 15870042 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECiSe
Number of subjects: 40
Study 15870042 — intervention group
Group type: COMPARATOR
Intervention: Standard heart-lung machine (Control)
Number of subjects: 40
Study 12065173 — intervention group
Group type: EXPERIMENTAL
Intervention: EV+LNG (Group A)
Number of subjects: 30
Study 12065173 — intervention group
Group type: EXPERIMENTAL
Intervention: TSE2+TSLNG (Group C)
Number of subjects: 30
Study 12065173 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 30
Study 10361566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (up to 12 sessions)
Number of subjects: 400
Study 10361566 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study 10361566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 400
Study 8542914 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg administered by an auto‐injector
Number of subjects: 246
Study 8542914 — intervention group
Group type: COMPARATOR
Intervention: Usual acute migraine treatments
Number of subjects: 246
Study 2361567 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg frusemide/2.5 mg amiloride
Number of subjects: 0
Study 2361567 — intervention group
Group type: COMPARATOR
Intervention: 20 mg frusemide
Number of subjects: 0
Study 2361567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 531993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) three times daily
Number of subjects: 24
Study 531993 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (75 mg) three times daily
Number of subjects: 24
Study 531993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) plus Dipyridamole (75 mg) three times daily
Number of subjects: 24
Study 531993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31867908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen needling treatment
Number of subjects: 64
Study 31867908 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicines and conventional needling treatment
Number of subjects: 64
Study 28710202 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) combined with Traditional Programme (TP)
Number of subjects: 120
Study 28710202 — intervention group
Group type: COMPARATOR
Intervention: Traditional Programme (TP)
Number of subjects: 120
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual detection responses
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual responses
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus activity in the prefrontal cortex
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus activity in the default-mode network
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststimulus connectivity between prefrontal cortex and visual system
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal visual stream activity
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestimulus activity in the auditory cortex
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststimulus neural coupling between auditory and sensorimotor cortex
Number of subjects: 0
Study 26085631 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectivity with the default-mode network
Number of subjects: 0
Study 23689595 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg vitamin C/day
Number of subjects: 33
Study 23689595 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg vitamin C/day
Number of subjects: 33
Study 23689595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23689595 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (unspecified dose)
Number of subjects: 33
Study 21349889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial osteopathy (six sessions with a registered osteopath)
Number of subjects: 142
Study 21349889 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list with partial attention control)
Number of subjects: 142
Study 19427810 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual massage and mobilization of the feet and ankles
Number of subjects: 28
Study 19427810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17716335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GH/m(2)/day (group A, n = 34)
Number of subjects: 75
Study 17716335 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, n = 23)
Number of subjects: 75
Study 15100514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc methylene diphosphonate (Tc‐MDP) bone scan
Number of subjects: 77
Study 15100514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc hexamethylproplyene amine oxime (Tc‐HMPAO) labelled white blood cell (WBC) scan
Number of subjects: 77
Study 15100514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc microcolloid bone marrow (BM) scan
Number of subjects: 77
Study 15100514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of WBC scan and BM scan
Number of subjects: 77
Study 12714834 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 52
Study 12714834 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin with aspirin
Number of subjects: 52
Study 9839101 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5‐5 mg twice a day)
Number of subjects: 883
Study 9839101 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5‐25 mg twice a day)
Number of subjects: 883
Study 7916399 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cervical examinations at every prenatal visit (experimental group)
Number of subjects: 5602
Study 7916399 — intervention group
Group type: COMPARATOR
Intervention: Avoidance of cervical examination if possible (control group)
Number of subjects: 5602
Study 2815969 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virion trivalent influenza vaccine (A/Leningrad/360/86(H3N2), A/Taiwan/5/87 and B/Ann Arbor/1/86)
Number of subjects: 72
Study 2815969 — intervention group
Group type: COMPARATOR
Intervention: Control group (young adults)
Number of subjects: 72
Study 1173059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous propranolol
Number of subjects: 15
Study 1173059 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of intravenous tolamolol
Number of subjects: 15
Study 1173059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous tolamolol
Number of subjects: 15
Study 1173059 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 15
Study 30684589 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement stress
Number of subjects: 168
Study 30684589 — intervention group
Group type: EXPERIMENTAL
Intervention: Social rejection stress
Number of subjects: 168
Study 30684589 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 168
Study 27502307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 497
Study 27502307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 26358285 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 26358285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 26358285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16492
Study 26358285 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer diabetes duration
Number of subjects: 16492
Study 24687538 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated IT-based telephone monitoring system for symptom reporting
Number of subjects: 250
Study 24687538 — intervention group
Group type: COMPARATOR
Intervention: Control group (attentional control)
Number of subjects: 250
Study 22113257 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based exercise intervention (10 phone calls over 16 weeks)
Number of subjects: 121
Study 22113257 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based exercise intervention
Number of subjects: 121
Study 22113257 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 121
Study 20007011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10mg b.i.d.)
Number of subjects: 146
Study 20007011 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 146
Study 18075905 — intervention group
Group type: EXPERIMENTAL
Intervention: TFJ stabilized
Number of subjects: 20
Study 18075905 — intervention group
Group type: EXPERIMENTAL
Intervention: TFJ not stabilized
Number of subjects: 20
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (carboplatin/etoposide)
Number of subjects: 76
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (ifosfamide/etoposide)
Number of subjects: 76
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (cyclophosphamide/etoposide)
Number of subjects: 76
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 76
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-Free Survival (EFS)
Number of subjects: 76
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to an event
Number of subjects: 76
Study 16315242 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to HDCT
Number of subjects: 76
Study 12096385 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission of digitized clinical records supported by access to video and data conferencing
Number of subjects: 0
Study 12096385 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9458199 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiprilose hydrochloride
Number of subjects: 286
Study 9458199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 7636658 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 300 units/kg per week
Number of subjects: 97
Study 7636658 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 750 units/kg per week
Number of subjects: 97
Study 7636658 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 97
Study 2750683 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial regimens that suppressed menaquinone‐producing intestinal microflora and contained an N‐methylthiotetrazole (NMTT) moiety
Number of subjects: 34
Study 2750683 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial agents that preserved the microflora and contained no NMTT moiety
Number of subjects: 34
Study 352631 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide-neomycin-amphotericin ointment
Number of subjects: 50
Study 352631 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone ointment
Number of subjects: 50
Study 31724191 — intervention group
Group type: EXPERIMENTAL
Intervention: BCD-020
Number of subjects: 174
Study 31724191 — intervention group
Group type: COMPARATOR
Intervention: Comparator (reference rituximab)
Number of subjects: 174
Study 31724191 — intervention group
Group type: COMPARATOR
Intervention: Both BCD-020 and Comparator
Number of subjects: 174
Study 29739385 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented physical education program (270 minutes of weekly physical education)
Number of subjects: 312
Study 29739385 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented physical education program
Number of subjects: 312
Study 29739385 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity outcomes
Number of subjects: 312
Study 29931852 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (1 μg/kg before induction and 0.5 μg/(kg·h) maintenance)
Number of subjects: 54
Study 29931852 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 54
Study 29931852 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 54
Study 24867834 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A injection
Number of subjects: 0
Study 22659759 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% ketamine cream
Number of subjects: 17
Study 22659759 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 17
Study 20113941 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 58
Study 20113941 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 58
Study 18617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehomecare
Number of subjects: 284
Study 18617707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 16092677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (10 ml)
Number of subjects: 115
Study 16092677 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 115
Study 12117400 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 35000
Study 10598014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-propofol (propofol group, n = 20)
Number of subjects: 40
Study 10598014 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-ketamine (M-K group, n = 20)
Number of subjects: 40
Study 10598014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8607392 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 239
Study 8607392 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 239
Study 2021542 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (mustine, Oncovin, procarbazine, prednisone)
Number of subjects: 290
Study 2021542 — intervention group
Group type: COMPARATOR
Intervention: LOPP (Leukeran substituted for mustine)
Number of subjects: 290
Study 2021542 — intervention group
Group type: COMPARATOR
Intervention: LOPP
Number of subjects: 290
Study 2021542 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 290
Study 7081979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin-aminoglycoside combinations (cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; cefamandole and gentamicin)
Number of subjects: 199
Study 7081979 — intervention group
Group type: EXPERIMENTAL
Intervention: Children (cephalosporin-aminoglycoside combinations)
Number of subjects: 199
Study 7081979 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults (cephalosporin-aminoglycoside combinations)
Number of subjects: 199
Study 31482193 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation
Number of subjects: 426824
Study 31482193 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to alcohol dependence
Number of subjects: 426824
Study 31482193 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted alcohol and coffee intake
Number of subjects: 426824
Study 29053118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nooklerin (deanoli aceglumas) administered as add-on treatment at a daily dose of 1000 mg for 30 days
Number of subjects: 60
Study 29053118 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard psychopharmacological treatment without nooklerin
Number of subjects: 60
Study 25677355 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 110
Study 25677355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 110
Study 25677355 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Therapy
Number of subjects: 110
Study 25677355 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 110
Study 25677355 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT and Prolonged Exposure
Number of subjects: 110
Study 23937405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (AP), active application (APA)
Number of subjects: 31
Study 23937405 — intervention group
Group type: COMPARATOR
Intervention: Adper Prompt L‐Pop (AP), passive application (APP)
Number of subjects: 31